RecruitingPhase 2ACTRN12614000619640

The effect of Memantine on cognition disorders induced by Electroconvulsive therapy (ECT)

A double blind randomized clinical trial to evaluate the effect of oral memantine on the prevention of post ECT cognition disorders

Sponsor

Mohammad Abbasinazari

Enrollment

40 participants

Start Date

Feb 28, 2014

Study Type

Interventional

Conditions

Post ECT cognition disorders

Summary

one major complication of electroconvulsive therapy (ECT) is the potential for temporary mild to moderate cognitive impairment. Memantine (a NMDA antagonist agent) has a beneficial effect on cognition in patients with moderate to severe Alzheimer ’s disease. The purpose of this study was to assess the effectiveness of Memantine 5mg/d in the prevention of cognitive impairments during ECT treatment. A prospective, double blind, placebo controlled trial included 40 patients underwent ECT will be done. Patients will randomly select to receive either memantine 5 mg/d or a placebo. Drug or placebo started the day before doing ECT and continue throughout the fourth course of ECT. An objective measure of cognitive function is Modified Mental Status Examination (MMSE) and will be performed pre-ECT and post-ECT. Finally score of MMSE before and after ECT will be compare.

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 60 Yearss

Inclusion Criteria1

All patients between 18-60 years old undergoing ECT in the psychosomatic ward of Taleghani hospital(Tehran, Iran) with informed consent

Exclusion Criteria1

patients with renal failure or hepatic failure, those with cardiac block, patients using medications with anticholinergic or NMDA(N-methyl D aspartate) antagonistic effect,pregnant and brearstfeeding women

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Administration of oral memantine 5 mg daily that will be start the day before doing ECT. Adherence monitoring will be done by counting tablet return by patients.Meantime 5mg daily continue throughout

Administration of oral memantine 5 mg daily that will be start the day before doing ECT. Adherence monitoring will be done by counting tablet return by patients.Meantime 5mg daily continue throughout the fourth course of ECT (last dose at fourth course of ECT)

Locations(1)

Tehran, Iran, Islamic Republic Of

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12614000619640